#Predictive Biomarkers

[creativeera]

Cancer Biomarkers Market is Trending by Increasing Personalized Care

Cancer biomarkers are biological molecules found in blood, tissues, or other body fluids whose presence indicates normal or abnormal processes, or conditions of concern regarding health. They are used in patient diagnosis, staging, treatment selection, monitoring of cancer progression or recurrence. Cancer biomarkers help in early cancer detection and assessing the likelihood of cancer recurrence after treatment. They play an important role in cancer risk assessment, screening, diagnosis, prognosis, and predicting treatment response for a variety of cancers. With increasing technological advancements, more personalized and targeted treatment options are emerging. This is fueling the demand for cancer biomarkers to help physicians detect cancer in early stages, determine the best treatment for each patient, monitor the effectiveness of treatment, and check for signs of recurrence.

The Global Cancer Biomarkers Market is estimated to be valued at US$ 25.60 billion in 2024 and is expected to exhibit a CAGR of 12% over the forecast period 2024 to 2031. Key Takeaways Key players operating in the Cancer Biomarkers are Schlumberger Limited, Rockwell Automation Inc., SIS-TECH Solutions LP, Emerson Electric Company, HIMA Paul Hildebrandt GmbH, Honeywell International Inc., Siemens AG, Yokogawa Electric Corporation, Schneider Electric SE, and ABB Ltd. The increasing prevalence of cancer globally has boosted the usage of cancer biomarkers. Rising demand for non-invasive diagnostic techniques along with increasing funding for cancer research are fueling the market growth. Growing awareness regarding the benefits of early detection of cancer is further driving the demand for cancer biomarkers. The growing Cancer Biomarkers Market demand for personalized medicine is also propelling the demand for cancer biomarkers. Personalized medicine focuses on classifying individuals based on their susceptibility and likely response to particular treatment. This allows clinicians to choose the most safe and effective treatment for each patient. Many companies are increasingly investing in biomarker research and development to introduce innovative cancer diagnostics and targeted therapies. The increasing global incidence of cancer has encouraged market players to expand their geographical presence. Emerging countries in Asia Pacific and Latin America offer lucrative opportunities for players due to growing healthcare investments, favorable government policies, and rising patient disposable incomes in these regions. Players are also focusing on partnerships, mergers, acquisitions, and collaborations with research institutes and biotechs to strengthen their product portfolios and geographical footprints. Market Key Trends Next-generation sequencing (NGS) has emerged as a key trend in the global cancer biomarkers market. NGS helps to discover and validate novel biomarkers by generating huge amounts of DNA sequence data from tumor and normal samples. It allows comprehensive genomic profiling of tumors to guide treatment decisions. NGS enables the analysis of multiple biomarkers simultaneously compared to traditional techniques. This allows physicians to obtain a complete molecular profile of the tumor specific to each patient for precision diagnosis and treatment selection.

Porter’s Analysis Threat of new entrants: High capital requirements and strong intellectual property rights protections limit new entrants in this competitive market.

Bargaining power of buyers: Large pharmaceutical companies have significant bargaining power over biotech companies developing novel biomarkers, putting pricing pressure.

Bargaining power of suppliers: Suppliers of analytical instruments and clinical testing kits have some bargaining power as they provide core tools and technologies needed by most companies in this space.

Threat of new substitutes: Biomarkers able to better diagnose, monitor, or predict therapeutic responses could emerge as substitutes over time.

Competitive rivalry: Intense competition exists among large pharmaceutical companies and smaller biotech firms to develop and commercialize novel cancer biomarker diagnostic tests and services. Geographical Regions North America currently accounts for the largest share of the global cancer biomarkers market, in terms of value, owing to the high adoption of advanced cancer diagnostic techniques and presence of leading biomarker testing companies in the region. The Asia Pacific market is expected to grow at the fastest rate during the forecast period, due to growing awareness regarding early cancer detection, increasing healthcare expenditure, and expanding base of pharma & biotech companies in China, India, and other Asia Pacific countries.

Get more insights on Cancer Biomarkers Market

For Deeper Insights, Find the Report in the Language that You want

French

German

Italian

Russian

Japanese

Chinese

Korean

Portuguese

Vaagisha brings over three years of expertise as a content editor in the market research domain. Originally a creative writer, she discovered her passion for editing, combining her flair for writing with a meticulous eye for detail. Her ability to craft and refine compelling content makes her an invaluable asset in delivering polished and engaging write-ups.

(LinkedIn: https://www.linkedin.com/in/vaagisha-singh-8080b91)

[johniac]

SciTech Chronicles. . . . . .May 16th, 2025

[reasonsforhope]

"A medical technology company in Australia is aiming for a world-first: it wants to launch a blood test for endometriosis (sometimes called 'endo' for short) within the first half of this year [2025].

In a recent peer-reviewed trial, its novel test proved 99.7 percent accurate at distinguishing severe cases of endometriosis from patients without the disease but with similar symptoms.

Even in the early stages of the disease, when blood markers may be harder to pick out, the test's accuracy remained over 85 percent.

The company behind the patent, Proteomics International, says it is currently adapting the method "for use in a clinical environment," with a target launch date in Australia for the second quarter of this year [2025].

The test is called PromarkerEndo.

"This advancement marks a significant step toward non-invasive, personalized care for a condition that has long been underserved by current medical approaches," managing director of Proteomics International Richard Lipscombe said in a press release from December 30.

Endometriosis is a common inflammatory disease that occurs when tissue similar to the lining of the uterus grows in other parts of the body, forming lesions. The disease can be very painful, and yet the average patient often suffers debilitating symptoms for up to seven years before they are properly diagnosed.

While there are numerous reasons for such a long delay, symptoms of endometriosis are often highly variable, unpredictable, difficult to measure or describe, and dismissed or overlooked by doctors.

Today, the only definitive way to diagnose endometriosis is via keyhole surgery called a laparoscopy, which is expensive, invasive, and carries risks.

Proteomics International is hoping to change that.

In collaboration with researchers at the University of Melbourne and the Royal Women's Hospital, the company compared the bloodwork data from 749 participants of mostly European descent.

Some had endometriosis and others had symptoms that were similar to endo but without the lesions. All participants had a laparoscopy to confirm the presence or absence of the disease.

Sifting through the bloodwork, researchers ran several different algorithms to figure out which proteins in the blood were best at predicting endometriosis of varying stages.

Building on previous research, a panel of 10 proteins showed a "clear association" with endometriosis.

For years now, scientists have investigated possible blood biomarkers of endometriosis to see if they could differentiate between those who have endo and those who do not. Similar to cancerous tumors, endo lesions can establish their own blood supply, and if cervical cancer can be diagnosed via a blood test, it seemed possible that endometriosis could be, too...

Proteomics International claims patents for PromarkerEndo are "pending in all major jurisdictions," starting first in Australia.

It remains to be seen if the company's blood test lives up to the hype and is approved by the Australian Therapeutic Goods Administration (TGA). But that's not outside the realm of possibility.

In November of 2023, some researchers predicted that a "reliable non-invasive biomarker for endometriosis is highly likely in the coming years."

Perhaps this is the year."

-via ScienceAlert, January 9, 2025

--

Note: As someone with endometriosis, let me say that this is a HUGE deal. The condition is incredibly common, incredibly understudied, and incredibly often dismissed. Massive sexism at work here.

I got very lucky and got diagnosed after about 6 months of chronic pain (and extra extra lucky, because my pain went away with medication). But as the article says, the average time to diagnosis is seven years.

Being able to confirm endometriosis diagnoses/rates without invasive surgery will also lead to huge progress in studying/creating treatments for endo.

And fyi: If you have a period that is so painful that you can't stand up, or have to go home from school/work, or vomit, or anything else debilitating (or if any of those things apply if you forget to take pain meds), that is NOT NORMAL, and you should talk to a competent gynecologist asap.

[scichores]

Fascinating Role of Genomics in Drug Discovery and Development

This article dives deep into the significance of genomics in drug discovery and development, highlighting well-known genomic-based drug development services that are driving the future of pharmaceutical therapies. #genomics #drugdiscovery

A scientist using a whole genome DNA sequencer, in order to determine the “DNA fingerprint” of a specific bacterium. Original image sourced from US Government department: Public Health Image Library, Centers for Disease Control and Prevention. Under US law this image is copyright free, please credit the government department whenever you can”. by Centers for Disease Control and Prevention is…

[mindblowingscience]

Scientists have figured out a non-invasive way to determine if a transplanted organ is failing to take in a patient – no matter if it's a kidney, liver, lung, or heart. It's the first time that biomarkers of dysfunction have matched across multiple types of transplanted organs, and it hints at the possibility of a blood test that can diagnose early rejection in all transplant scenarios – a tool that doesn't yet exist. If more research is done, the newly identified biomarkers could even be used to differentiate between various types of organ rejection, including immune issues, inadequate blood supply, or maladaptive repairs.

Continue Reading.

[covid-safer-hotties]

The proteome content of blood clots observed under different conditions: successful role in predicting clot amyloid(ogenicity) - Preprint Posted Dec 3, 2024

A preprint I'll be keeping my eye on: What do Covid and Sepsis have in common? More than you think or is comfortable. Could lead to better treatment, though.

Abstract A recent analysis compared the proteome of (i) blood clots seen in two diseases – sepsis and long COVID – when blood was known to have clotted into an amyloid microclot form (as judged by staining with the fluorogenic amyloid stain thioflavin T) with (ii) that of those non-amy-loid clots considered to have formed normally. Such fibrinaloid microclots are also relatively resistant to fibrinolysis. The proteins that the amyloid microclots contained differed markedly both from the soluble proteome of typical plasma and that of normal clots, and also between the disease studies (an acute syndrome in the form of sepsis in an ITU and a chronic disease represented by Long COVID). Many proteins in the amyloid microclots were low in concentration in plasma and were effectively accumulated into the fibres, whereas many other abundant plasma proteins were excluded. The proteins found in the microclots associated with the diseases also tended to be themselves amyloidogenic. We here ask effectively the inverse question. This is: can the clot proteome tell us whether the clots associated with a particular disease contained proteins that are observed uniquely (or are highly over-represented) in known amyloid clots relative to normal clots, and thus were in fact amyloid in nature? The answer is in the affirmative in a variety of major coagulopathies, viz. venous thromboembolism, pulmonary embolism, deep vein thrombosis, various cardiac issues, and ischaemic stroke. Galectin-3-binding protein and thrombospondin-1 seem to be especially widely associated with amyloid-type clots, and the latter has indeed been shown to be incorporated into growing fibrin fibres. These may consequently provide useful biomarkers with a mechanistic basis.

[dykesynthezoid]

Can’t believe I have to say this but birth control cannot give you PCOS. PCOS has genetic and environmental factors that have nothing to do w BC. Researchers can predict the later development of PCOS from biomarkers present when you’re a baby. If you went on birth control as a teenager and then just recently went off it as an adult and started having PCOS symptoms it’s bc birth control is often used to treat PCOS. It was just masking the PCOS that whole time, and you were relatively young when you first started taking it, so your symptoms hadn’t become obvious yet.

Not that hormones can’t have a huge impact on health, but you should be wary when any woman starts talking about how birth control “ruined her body” bc even if she’s telling the truth there’s a good chance that she actually has a serious underlying health condition that became more apparent by either stopping or starting birth control. It does not mean birth control itself is evil. The problem is the lack of research into health conditions that affect women and how they affect women. It’s not that your woman-body is so wild and unpredictable that there’s no telling what some mysterious female hormones could do to you.

Also not all hormonal birth control is going to affect your body the same anyway. People tend to have very different reactions to high estrogen and low estrogen pills respectively, for example (including myself). It’s completely understandable to be wary of how stopping/starting the pill could affect your body, but keep in mind that most of the changes actually triggered by that would be a. temporary and b. could be managed by switching to another form of birth control or adding a separate medication or treatment to manage symptoms if you really need to be on that specific form of it.

[darkmaga-returns]

By Nicolas Hulscher, MPH

The study titled, Hypothesis: ultrasonography can document dynamic in vivo rouleaux formation due to mobile phone exposure, was recently published in Frontiers in Cardiovascular Medicine:

Carrying a cellphone against the body has become commonplace in our world replete with smartphones. Acute and chronic health effects caused by these devices emitting radiofrequency radiation from multiple antennas have not been well evaluated. In this study, the popliteal vein of a healthy volunteer was imaged with ultrasonography prior to and following the placement of an idle, but active smartphone against her knee for 5 min [Apple iPhone XR smartphone operating on the AT&T mobile network—Wi-Fi, Bluetooth, and cellular data antennas were all turned on, but the phone was otherwise inactive and idle.]. Pre-exposure longitudinal sonographic images demonstrate a normal anechoic lumen to the popliteal vein. Images obtained 5 min after direct skin exposure to the smartphone demonstrate a dramatic change in the acoustic appearance of the vessel. The interior of the vessel became coarsely hypoechoic with sluggish flow seen in real-time images, a typical sonographic appearance for rouleaux formation. A follow up examination performed 5 min after the subject walked around yielded continued rouleaux formation in the popliteal vein, albeit less dramatic than that observed immediately post exposure. This revolutionary in vivo method to assess radiofrequency radiation induced rouleaux formation should be further pursued in the general population to determine its prevalence and if its occurrence provides a unique biomarker of exposure that may predict morbidity.

To illustrate this study in an easy-to-understand diagram, I created the following graphic:

[creativeera]

Cancer Biomarkers Market Poised to Exhibit a CAGR of 7.3% by 2031

Cancer biomarkers are substances whose presence is indicative of some biological condition, processes, or pathology. They can be used for cancer diagnosis or checking effectiveness of treatment. Being non-invasive procedures, demand for cancer biomarkers is growing rapidly. They aid in early detection of cancer during screening programs and reduce cost of cancer treatment. Global cancer biomarkers market is estimated to be valued at USD 25.60 Bn in 2024 and is expected to reach USD 59.01 Bn by 2031, exhibiting a compound annual growth rate (CAGR) of 12.7% from 2024 to 2031.

Key Takeaways Key players operating in the Cancer Biomarkers market are Schlumberger Limited, Rockwell Automation Inc., SIS-TECH Solutions LP, Emerson Electric Company, HIMA Paul Hildebrandt GmbH, Honeywell International Inc., Siemens AG, Yokogawa Electric Corporation, Schneider Electric SE, and ABB Ltd. They are investing heavily in biomarker detection methods and panels targeting unmet clinical needs. Rising incidence of cancer across the world is driving for Cancer Biomarkers Market Demand. Biomarkers help in cancer screening and detecting disease at early stages. This improves treatment outcomes and survival rates significantly. Initiatives by governments and cancer councils to spread cancer awareness are also boosting the market. Global expansion strategies adopted by leading players are expected to support market growth during the forecast period. They are expanding their footprint in emerging markets of Asia Pacific, Latin America, and Middle East & Africa to tap the high growth opportunities. This will increase access to advanced cancer diagnostic solutions. Market Key Trends The use of artificial intelligence and machine learning algorithms to discover novel biomarkers from large datasets is a key trend in the market. It helps accelerate the process of biomarker identification. Genomic and proteomic biomarkers are also gaining traction for their role in cancer detection as well as tracking cancer progression and drug response. Development of personalized diagnostics based on multi-omics approaches and liquid biopsy tests are some other trends expected to shape the market.

Porter’s Analysis Threat of new entrants: The cancer biomarkers market requires huge capital investments in R&D for developing novel biomarkers and testing kits which makes the entry difficult for new players. Bargaining power of buyers: Buyers have moderate bargaining power in this market as there are many players offering similar cancer biomarker testing services. Bargaining power of suppliers: Suppliers have low bargaining power due to availability of alternative raw material suppliers in the market. Threat of new substitutes: Substitutes have low threat as there are limited substitutes available for cancer biomarker tests. Competitive rivalry: The market is highly competitive due to presence of many global as well as regional players. Geographical Regions North America region accounts for the largest share of the cancer biomarkers market in terms of value due to presence of major players, rising healthcare expenditure and increasing prevalence of cancer in the region. Asia Pacific is expected to grow at the fastest CAGR during the forecast period owing to increasing awareness regarding cancer, improving healthcare infrastructure and rising access to diagnostic services in emerging economies of China and India in this region.

Get more insights on Cancer Biomarkers Market

About Author:

Money Singh is a seasoned content writer with over four years of experience in the market research sector. Her expertise spans various industries, including food and beverages, biotechnology, chemical and materials, defense and aerospace, consumer goods, etc. (https://www.linkedin.com/in/money-singh-590844163)

[spacetimewithstuartgary]

Astronauts' eyes weaken during long space missions, raising concerns for Mars travel

The low levels of gravity (microgravity) in space cause significant changes in astronauts' eyes and vision after six to 12 months aboard the International Space Station (ISS), according to a study published in the IEEE Open Journal of Engineering in Medicine and Biology.

Université de Montréal ophthalmologist Santiago Costantino found that at least 70% of astronauts on the ISS have been affected by spaceflight-associated neuro-ocular syndrome, or SANS.

In the biophotonics research unit he runs at the UdeM-affiliated Maisonneuve-Rosemont Hospital, Costantino assembled a group of researchers to identify the biomechanical changes responsible for this disorder.

They analyzed data collected by the Canadian team at NASA on 13 astronauts who spent between 157 and 186 days on the ISS.

The subjects had an average age of 48 and came from the U.S., European, Japanese and Canadian space agencies; 31% were women; eight were on their first mission.

Three parameters involved

The researchers compared three ocular parameters before and after the astronauts' space missions: ocular rigidity, intraocular pressure, and ocular pulse amplitude.

They measured ocular rigidity using optical coherence tomography with a customized video module to improve the quality of images of the choroid. The other two parameters, intraocular pressure and ocular pulse amplitude, were measured using tonometry.

The study found significant changes in the biomechanical properties of the astronauts' eyes: a 33% decrease in ocular rigidity, an 11% decrease in intraocular pressure, and a 25% reduction in ocular pulse amplitude.

These changes were accompanied by symptoms including reduced eye size, altered focal field and, in some cases, optic nerve edema and retinal folds.

The researchers also found that five astronauts had a choroidal thickness greater than 400 micrometers, which was not correlated with age, gender or previous space experience.

"Weightlessness alters the distribution of blood in the body, increasing blood flow to the head and slowing venous circulation in the eye," explained Costantino. "This is probably what causes the expansion of the choroid, the vascular layer that nourishes the retina."

Long-lasting changes

According to the researchers, the expansion of the choroid during weightlessness could stretch the collagen in the sclera, the white outer layer of the eye, causing long-lasting changes in the eye's mechanical properties.

They also believe that blood pulsations under microgravity can create a water-hammer effect in which sudden changes in blood-flow-pressure cause a mechanical shock to the eye, leading to significant tissue remodeling.

Eyes return to normal

According to the researchers, these ocular changes are generally not cause for concern when the space mission lasts six to 12 months. Although 80% of the astronauts they studied developed at least one symptom, their eyes returned to normal once back on Earth.

In most cases, wearing corrective eyeglasses was sufficient to correct the symptoms developed aboard the ISS.

However, the research community and international space agencies are cautious about the consequences of longer missions, such as a flight to Mars. The eye-health effects of prolonged exposure to microgravity remain unknown, and no preventive or palliative measures now exist.

The Maisonneuve-Rosemont research team is waiting for more data from NASA to continue its investigations.

"The observed changes in the mechanical properties of the eye could serve as biomarkers to predict the development of SANS (spaceflight-associated neuro-ocular syndrome)," said Costantino.

"This would help identify at-risk astronauts before they develop serious eye problems during long-duration missions."

[biopractify]

How AI is Being Used to Predict Diseases from Genomic Data

Introduction

Ever wonder if science fiction got one thing right about the future of healthcare? Turns out, it might be the idea that computers will one day predict diseases before they strike. Thanks to Artificial Intelligence (AI) and genomics, we’re well on our way to making that a reality. From decoding the human genome at lightning speeds to spotting hidden disease patterns that even experts can’t see, AI-powered genomics is revolutionizing preventative care.

This article explores how AI is applied to genomic data, why it matters for the future of medicine, and what breakthroughs are on the horizon. Whether you’re a tech enthusiast, a healthcare professional, or simply curious about the potential of your own DNA, keep reading to find out how AI is rewriting the rules for disease prediction.

1. The Genomic Data Boom

In 2003, scientists completed the Human Genome Project, mapping out 3.2 billion base pairs in our DNA. Since then, genomic sequencing has become faster and more affordable, creating a flood of genetic data. However, sifting through that data by hand to predict diseases is nearly impossible. Enter machine learning—a key subset of AI that excels at identifying patterns in massive, complex datasets.

Why It Matters:

Reduced analysis time: Machine learning algorithms can sort through billions of base pairs in a fraction of the time it would take humans.

Actionable insights: Pinpointing which genes are associated with certain illnesses can lead to early diagnoses and personalized treatments.

2. AI’s Role in Early Disease Detection

Cancer: Imagine detecting cancerous changes in cells before a single tumor forms. By analyzing subtle genomic variants, AI can flag the earliest indicators of diseases such as breast, lung, or prostate cancer. Neurodegenerative Disorders: Alzheimer’s and Parkinson’s often remain undiagnosed until noticeable symptoms appear. AI tools scour genetic data to highlight risk factors and potentially allow for interventions years before traditional symptom-based diagnoses. Rare Diseases: Genetic disorders like Cystic Fibrosis or Huntington’s disease can be complex to diagnose. AI helps identify critical gene mutations, speeding up the path to diagnosis and paving the way for more targeted treatments.

Real-World Impact:

A patient’s entire genomic sequence is analyzed alongside millions of others, spotting tiny “red flags” for diseases.

Doctors can then focus on prevention: lifestyle changes, close monitoring, or early intervention.

3. The Magic of Machine Learning in Genomics

Supervised Learning: Models are fed labeled data—genomic profiles of patients who have certain diseases and those who do not. The AI learns patterns in the DNA that correlate with the disease.

Unsupervised Learning: This is where AI digs into unlabeled data, discovering hidden clusters and relationships. This can reveal brand-new biomarkers or gene mutations nobody suspected were relevant.

Deep Learning: Think of this as AI with “layers”—neural networks that continuously refine their understanding of gene sequences. They’re especially good at pinpointing complex, non-obvious patterns.

4. Personalized Medicine: The Future is Now

We often talk about “one-size-fits-all” medicine, but that approach ignores unique differences in our genes. Precision Medicine flips that on its head by tailoring treatments to your genetic profile, making therapies more effective and reducing side effects. By identifying which treatments you’re likely to respond to, AI can save time, money, and—most importantly—lives.

Pharmacogenomics (the study of how genes affect a person’s response to drugs) is one area booming with potential. Predictive AI models can identify drug-gene interactions, guiding doctors to prescribe the right medication at the right dose the first time.

5. Breaking Down Barriers and Ethical Considerations

1. Data Privacy

Genomic data is incredibly personal. AI companies and healthcare providers must ensure compliance with regulations like HIPAA and GDPR to keep that data safe.

2. Algorithmic Bias

AI is only as good as the data it trains on. Lack of diversity in genomic datasets can lead to inaccuracies or inequalities in healthcare outcomes.

3. Cost and Accessibility

While the price of DNA sequencing has dropped significantly, integrating AI-driven genomic testing into mainstream healthcare systems still faces cost and infrastructure challenges.

6. What’s Next?

Realtime Genomic Tracking: We can imagine a future where your genome is part of your regular health check-up—analyzed continuously by AI to catch new mutations as they develop.

Wider Disease Scope: AI’s role will likely expand beyond predicting just one or two types of conditions. Cardiovascular diseases, autoimmune disorders, and metabolic syndromes are all on the list of potential AI breakthroughs.

Collaborative Ecosystems: Tech giants, pharmaceutical companies, and healthcare providers are increasingly partnering to pool resources and data, accelerating the path to life-changing genomic discoveries.

7. Why You Should Care

This isn’t just about futuristic research; it’s a glimpse of tomorrow’s medicine. The more we rely on AI for genomic analysis, the more proactive we can be about our health. From drastically reducing the time to diagnose rare diseases to providing tailor-made treatments for common ones, AI is reshaping how we prevent and treat illnesses on a global scale.

Final Thoughts: Shaping the Future of Genomic Healthcare

AI’s impact on disease prediction through genomic data isn’t just a high-tech novelty—it’s a turning point in how we approach healthcare. Early detection, faster diagnosis, personalized treatment—these are no longer mere dreams but tangible realities thanks to the synergy of big data and cutting-edge machine learning.

As we address challenges like data privacy and algorithmic bias, one thing’s certain: the future of healthcare will be defined by how well we harness the power of our own genetic codes. If you’re as excited as we are about this transformative journey, share this post, spark discussions, and help spread the word about the life-changing possibilities of AI-driven genomics.

[pandemic-info]

Researchers Develop Algorithm To Predict Whether A Person Gets Long Covid

Researchers Develop Algorithm To Predict Whether A Person Gets Long Covid

https://www.forbes.com/sites/willskipworth/2023/09/25/researchers-develop-algorithm-to-predict-whether-a-person-gets-long-covid/?sh=442ada729259

[healthcarereport2032]

Biomarkers Market Comprehensive Analysis, Forecast to 2032

The global biomarkers market was valued at USD 38.41 billion in 2018 and is expected to soar to USD 190.81 billion by 2032, registering a robust CAGR of 12.1% over the forecast period. In 2018, North America led the biomarkers market, accounting for a dominant market share of 38.53%.

A biomarker, or biological marker, refers to a measurable indicator of the biological state or condition of an organ, tissue, or cell. Biomarkers play a crucial role in medicine, safety assessments, and drug discovery and development. They are classified into various types based on their functions, including diagnostic biomarkers, prognostic biomarkers, predictive biomarkers, and more. Biomarkers significantly contribute to enhancing the drug development process and advancing biomedical research. Additionally, based on biological characteristics, biomarkers are further categorized into genomics, proteomics, and other segments.

The growing use of biomarkers in diagnostic applications is a major driver propelling the expansion of the biomarkers industry. Increasing investments in research and development by biotechnology and pharmaceutical companies, along with the rising global prevalence of cancer, are key biomarkers market trends fueling demand. These factors are collectively accelerating the growth and development of the biomarkers market.

Request a Free Sample PDF: https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/biomarkers-market-102173

Biomarkers Market: Market Trend The Biomarkers Market is experiencing a significant surge in interest due to advancements in precision medicine and personalized therapies. Growing adoption of biomarkers in drug discovery and development is reshaping pharmaceutical strategies. Liquid biopsy and genomic biomarkers are gaining traction as they offer non-invasive diagnostic solutions with high accuracy. Furthermore, technological advancements in bioinformatics and high-throughput screening are accelerating the pace of biomarker research, contributing to the dynamic growth of the Biomarkers Market.

Biomarkers Market: Market Growth The Biomarkers Market is poised for robust growth, driven by increasing incidences of chronic diseases such as cancer, cardiovascular disorders, and neurological conditions. The demand for early and accurate diagnosis is pushing healthcare providers to integrate biomarker-based testing into their clinical workflows. Moreover, growing investments in research and development, along with favorable regulatory approvals, are expected to further propel the Biomarkers Market. The increasing focus on companion diagnostics is also playing a crucial role in market expansion.

List Of Key Companies Covered:

F. Hoffmann-La Roche Ltd.

Abbott

Thermo Fisher Scientific

Bio-Rad Laboratories, Inc.

CENTOGENE N.V.

Axon Medchem

Sino Biological Inc.,

R&D System

BioVision Inc.

Myriad RBM

Other players

Biomarkers Market: Market Segmentation The Biomarkers Market is comprehensively segmented based on type, application, disease indication, and end-user. In terms of type, the Biomarkers Market includes safety biomarkers, efficacy biomarkers, validation biomarkers, and predictive biomarkers. Among these, predictive biomarkers hold a dominant share in the Biomarkers Market due to their critical role in forecasting disease risk and response to specific treatments.

When categorized by application, the Biomarkers Market covers diagnostics, drug discovery & development, personalized medicine, and disease risk assessment. Diagnostic applications lead the Biomarkers Market, as healthcare providers increasingly rely on biomarkers for early detection and disease monitoring. The integration of biomarkers in drug development pipelines is also expanding, reinforcing the Biomarkers Market's role in improving clinical trial success rates.

Based on disease indication, the Biomarkers Market segments include cancer, cardiovascular diseases, neurological disorders, and infectious diseases. The cancer segment commands the largest share in the Biomarkers Market, as oncology research heavily depends on biomarkers for identifying genetic mutations and predicting therapy responses. However, the application of biomarkers in cardiovascular and neurological diseases is rapidly growing, further diversifying the scope of the Biomarkers Market.

In terms of end-users, the Biomarkers Market encompasses hospitals & clinics, academic & research institutes, pharmaceutical & biotechnology companies, and diagnostic laboratories. Pharmaceutical and biotechnology companies represent a significant portion of the Biomarkers Market, given their continuous efforts to develop targeted therapies. Diagnostic laboratories are also crucial players in the Biomarkers Market, driven by increasing demand for specialized testing services.

Biomarkers Market: Restraining Factors Despite its promising potential, the Biomarkers Market faces several challenges. High costs associated with biomarker validation and testing limit accessibility, especially in developing regions. Additionally, complexities in biomarker discovery and the need for stringent regulatory compliance can slow down the approval process. Ethical concerns related to genetic testing and data privacy also pose barriers to the broader adoption of biomarker technologies within the Biomarkers Market.

Biomarkers Market: Regional Analysis Geographically, North America dominates the Biomarkers Market, supported by advanced healthcare infrastructure, extensive research funding, and the presence of key industry players. Europe follows closely, benefiting from supportive government initiatives and increasing clinical trials. Meanwhile, the Asia-Pacific region is emerging as a high-potential market for biomarkers, fueled by rising healthcare investments, growing awareness, and an expanding patient base. Countries such as China and India are expected to contribute significantly to the growth of the Biomarkers Market in the coming years, making the region a focal point for future expansion.

Key Industry Developments:

In May 2021, QIAGEN N.V. announced the launch of its FDA-approved tissue companion diagnostic designed to detect the KRAS G12C mutation in non-small cell lung cancer (NSCLC) tumors. This advancement is set to strengthen QIAGEN's precision medicine portfolio, particularly in the field of lung cancer treatment. In April 2021, F. Hoffmann-La Roche Ltd revealed a series of five new applications for their cardiac biomarkers, utilizing the Elecsys technology. These biomarkers have demonstrated effectiveness in enhancing the management of cardiovascular diseases, further expanding Roche’s capabilities in cardiac care.